Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial-Reference-Cited by-同舟云学术

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

Published:2020-01 Issue:10218 Volume:395 Page:132-141
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Mateos Maria-Victoria,Cavo Michele,Blade Joan,Dimopoulos Meletios A,Suzuki Kenshi,Jakubowiak Andrzej,Knop Stefan,Doyen Chantal,Lucio Paulo,Nagy Zsolt,Pour Ludek,Cook Mark,Grosicki Sebastian,Crepaldi Andre,Liberati Anna Marina,Campbell Philip,Shelekhova Tatiana,Yoon Sung-Soo,Iosava Genadi,Fujisaki Tomoaki,Garg Mamta,Krevvata Maria,Chen Ying,Wang Jianping,Kudva Anupa,Ukropec Jon,Wroblewski Susan,Qi Ming,Kobos Rachel,San-Miguel Jesus

Publisher

Elsevier BV

Subject

General Medicine

Reference19 articles.

1. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Moreau;Ann Oncol,2017

2. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Moreau;Ann Oncol,2013

3. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79;Lammerts van Bueren;Blood,2014

4. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma;Overdijk;MAbs,2015

5. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcγ receptor-mediated cross-linking;Overdijk;J Immunol,2016

Cited by 291 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ixazomib-based frontline therapy followed by ixazomib maintenance in frail elderly newly diagnosed with multiple myeloma: a prospective multicenter study;eClinicalMedicine;2024-02

2. Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA;American Journal of Hematology;2024-01-31

3. Targeted immunotherapy: harnessing the immune system to battle multiple myeloma;Cell Death Discovery;2024-01-27

4. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma;New England Journal of Medicine;2024-01-25

5. Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review;Frontiers in Oncology;2024-01-25